Status:
ENROLLING_BY_INVITATION
Selective Plasma Adsorption of Extracellular DNA in Prevention of Intraoperative Metastasis in Pancreatic Cancer (Pilot Study)
Lead Sponsor:
Ilyinskaya Hospital, JSC
Collaborating Sponsors:
POCARD Ltd.
University Clinic of Lomonosov Moscow University
Conditions:
Pancreatic Ductal Adenocarcinoma (PDAC)
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
The goal of this clinical trial is to learn if selective plasma adsorption of extracellular DNA works to prevent formation of metastases of pancreatic cancer during surgical removal of the tumor. It w...
Detailed Description
Rationale for the study Tumor metastasis is the leading cause of cancer-associated mortality. In pancreatic cancer, metastases develop in more than 80% of patients (in 40-50% of cases in the first yea...
Eligibility Criteria
Inclusion
- \- Histologically and/or radiologically proven diagnosis of "Non-metastatic pancreatic ductal adenocarcinoma" of any localization, with ECOG physical status 0-1, who are scheduled for surgery for radical removal of the tumor, without previous chemotherapy (stage cT0-4 N0-2 M0) or after neoadjuvant chemotherapy (stage ycT0-4 N0-2 M0).
Exclusion
- Presence of other known oncological diseases.
- General contraindication to plasma adsorption (hypoproteinemia; acute cardiovascular failure; intolerance to foreign protein; decreased (less than 90/60 mm Hg) arterial pressure; gastrointestinal bleeding; acute cerebrovascular accidents; acute anemia; severe hypoxia).
Key Trial Info
Start Date :
April 4 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 4 2027
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT06967662
Start Date
April 4 2025
End Date
April 4 2027
Last Update
May 16 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ilyinskaya Hospital, JSC
Moscow, Moscow Oblast, Russia, 143421